UA111933C2 - Піролопіридини як інгібітори кінази - Google Patents

Піролопіридини як інгібітори кінази

Info

Publication number
UA111933C2
UA111933C2 UAA201015012A UAA201015012A UA111933C2 UA 111933 C2 UA111933 C2 UA 111933C2 UA A201015012 A UAA201015012 A UA A201015012A UA A201015012 A UAA201015012 A UA A201015012A UA 111933 C2 UA111933 C2 UA 111933C2
Authority
UA
Ukraine
Prior art keywords
pyrolopyridine
kinase inhibitors
compounds
formula
chk2
Prior art date
Application number
UAA201015012A
Other languages
English (en)
Inventor
Хюроу Івен Ле
Джеймс Ф. Блейк
Індрані У. Ганвордана
Пітер Дж. Мор
Ілай М. Уоллес
Бін Ван
Марк Чікареллі
Майкл ЛАЙОН
Original Assignee
Еррей Біофарма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA111933(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Еррей Біофарма Інк. filed Critical Еррей Біофарма Інк.
Publication of UA111933C2 publication Critical patent/UA111933C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Сполуки Формули І здатні інгібувати СНК1 та/або СНК2. Розкриті способи застосування сполук Формули І та їх стереоізомерів і фармацевтично прийнятних солей для діагностики, попередження або лікуванні таких розладів або супутніх патологічних станів у клітинах ссавців in vitro, in situ та in vivo.(I)
UAA201015012A 2008-05-13 2009-05-13 Піролопіридини як інгібітори кінази UA111933C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
PCT/US2009/043691 WO2009140320A1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
UA111933C2 true UA111933C2 (uk) 2016-07-11

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201015012A UA111933C2 (uk) 2008-05-13 2009-05-13 Піролопіридини як інгібітори кінази

Country Status (30)

Country Link
US (6) US8178131B2 (uk)
EP (2) EP2307409B1 (uk)
JP (2) JP5703212B2 (uk)
KR (2) KR101643426B1 (uk)
CN (3) CN102089307B (uk)
AR (1) AR071717A1 (uk)
AU (1) AU2009246402B2 (uk)
BR (1) BRPI0913580B8 (uk)
CA (1) CA2724262C (uk)
CL (1) CL2009001152A1 (uk)
CO (1) CO6321244A2 (uk)
CR (1) CR11803A (uk)
CY (1) CY1116692T1 (uk)
DK (1) DK2307409T3 (uk)
ES (1) ES2552643T3 (uk)
HK (2) HK1152035A1 (uk)
HR (1) HRP20151018T1 (uk)
HU (1) HUE026160T2 (uk)
IL (1) IL209258A (uk)
MX (1) MX2010012449A (uk)
NZ (1) NZ589318A (uk)
PH (1) PH12013501779A1 (uk)
PL (1) PL2307409T3 (uk)
PT (1) PT2307409E (uk)
RS (1) RS54358B1 (uk)
RU (1) RU2517194C2 (uk)
SI (1) SI2307409T1 (uk)
TW (2) TWI458727B (uk)
UA (1) UA111933C2 (uk)
WO (1) WO2009140320A1 (uk)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
US8372842B2 (en) 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
RU2567044C2 (ru) * 2009-04-11 2015-10-27 Эррэй Биофарма Инк. Ингибиторы 1 киназы контрольной точки клеточного цикла для усиления днк-повреждающих агентов
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
SG187742A1 (en) 2010-08-20 2013-03-28 Hutchison Medipharma Ltd Pyrrolopyrimidine compounds and uses thereof
RU2017127088A (ru) 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
PL2678329T3 (pl) 2011-02-25 2016-06-30 Array Biopharma Inc Związki triazolopirydyny jako inhibitory kinaz pim
WO2012148775A1 (en) 2011-04-29 2012-11-01 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
NZ702135A (en) 2012-04-23 2016-09-30 Genentech Inc Intermediates and processes for preparing 5-bromo-4-chloro-3-nitro-1h-pyrrolo[2,3-b]pyridine
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
CA2921956C (en) * 2013-08-22 2021-10-19 Genentech, Inc. Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
CN105722838B (zh) * 2013-09-25 2017-10-24 沃泰克斯药物股份有限公司 磷脂酰肌醇3‑激酶‑γ的选择性抑制剂
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016004305A2 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MA41599A (fr) 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
WO2017003090A1 (ko) 2015-06-30 2017-01-05 서울바이오시스 주식회사 Uv led가 적용된 포충기
DK3371165T3 (da) * 2015-11-04 2022-05-02 Merck Patent Gmbh Btk-inhibitor til anvendelse til behandling af kræft
EP3394064A1 (en) * 2015-12-22 2018-10-31 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
TW202014408A (zh) * 2018-07-03 2020-04-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病症的化合物及組合物
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP4182310A1 (en) 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
KR20240047338A (ko) 2021-05-14 2024-04-12 신닥스 파마슈티컬스, 인크. 메닌-mll 상호작용의 억제제

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173459A1 (en) * 1993-10-14 1995-04-20 Daniel T. Chu Quinolizinone type compounds
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
EP1274706A1 (en) 2000-04-18 2003-01-15 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
BR0313262A (pt) 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
AU2004220176A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
EP1756108A2 (en) * 2004-04-02 2007-02-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
JP4926943B2 (ja) * 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
MX2007012448A (es) 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
EP2354139A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
EP1932841B1 (en) * 2005-08-30 2014-01-01 Asahi Kasei Pharma Corporation Sulfonamide compound
JP5152922B2 (ja) 2005-10-06 2013-02-27 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
RU2008117298A (ru) 2005-10-06 2009-11-20 Шеринг Корпорейшн (US) Пиразолопиримидины как ингибиторы протеинкиназ
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
WO2008012635A2 (en) * 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
PE20091195A1 (es) 2007-11-07 2009-08-06 Schering Corp Nuevos moduladores de los puntos de control del ciclo celular y su uso en combinacion con inhibidores de quinasa de punto de control
WO2009089352A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
US8372842B2 (en) 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
RU2017127088A (ru) 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1

Also Published As

Publication number Publication date
CL2009001152A1 (es) 2009-10-16
CO6321244A2 (es) 2011-09-20
CR11803A (es) 2011-02-11
JP5703212B2 (ja) 2015-04-15
JP2015098482A (ja) 2015-05-28
CN102089307B (zh) 2015-07-01
HK1152035A1 (en) 2012-02-17
US20140243520A1 (en) 2014-08-28
MX2010012449A (es) 2011-05-25
PL2307409T3 (pl) 2016-01-29
US20160368916A1 (en) 2016-12-22
CY1116692T1 (el) 2017-03-15
US20110070317A1 (en) 2011-03-24
IL209258A (en) 2017-01-31
US9365568B2 (en) 2016-06-14
AU2009246402B2 (en) 2013-05-23
US8545897B2 (en) 2013-10-01
US9969727B2 (en) 2018-05-15
PH12013501779B1 (en) 2014-08-27
TW201002707A (en) 2010-01-16
SI2307409T1 (sl) 2015-11-30
US20140100369A1 (en) 2014-04-10
CN109942575A (zh) 2019-06-28
TWI554512B (zh) 2016-10-21
US8758830B2 (en) 2014-06-24
KR20110008102A (ko) 2011-01-25
TW201529573A (zh) 2015-08-01
AU2009246402A1 (en) 2009-11-19
AR071717A1 (es) 2010-07-07
RU2517194C2 (ru) 2014-05-27
CN102089307A (zh) 2011-06-08
BRPI0913580A2 (pt) 2015-10-20
EP2307409B1 (en) 2015-08-12
BRPI0913580B1 (pt) 2020-03-10
HUE026160T2 (en) 2016-05-30
CA2724262C (en) 2017-08-15
BRPI0913580B8 (pt) 2021-05-25
RU2010150786A (ru) 2012-06-20
TWI458727B (zh) 2014-11-01
RS54358B1 (en) 2016-04-28
WO2009140320A1 (en) 2009-11-19
CN104926810A (zh) 2015-09-23
US20130045286A1 (en) 2013-02-21
EP2990407B1 (en) 2019-10-16
KR101643426B1 (ko) 2016-07-27
JP2011520896A (ja) 2011-07-21
PT2307409E (pt) 2015-11-04
EP2990407A1 (en) 2016-03-02
US20150322061A1 (en) 2015-11-12
HRP20151018T1 (hr) 2015-10-23
US8178131B2 (en) 2012-05-15
KR20140093266A (ko) 2014-07-25
PH12013501779A1 (en) 2014-08-27
CN104926810B (zh) 2019-02-19
ES2552643T3 (es) 2015-12-01
HK1219950A1 (zh) 2017-04-21
IL209258A0 (en) 2011-01-31
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
NZ589318A (en) 2011-06-30
CA2724262A1 (en) 2009-11-19
US8981085B2 (en) 2015-03-17
KR101657856B1 (ko) 2016-09-19

Similar Documents

Publication Publication Date Title
UA111933C2 (uk) Піролопіридини як інгібітори кінази
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
MX2014005289A (es) Compuestos de piperazina alquilados.
MX2011009167A (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
UA116774C2 (uk) Інгібітори серин/треонінкінази
MX2014005285A (es) Compuestos biciclicos de piperazina.
EA201290957A1 (ru) Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
MX338504B (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
MY160349A (en) Pyridone and aza-pyridone compounds and methods of use
TW200800996A (en) Heterobicyclic pyrazole compounds and methods of use
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
PH12013502369A1 (en) Diazacarbazoles and methods of use
WO2008063202A3 (en) Heterobicyclic thiophene compounds for the treatment of cancer
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
TW200639163A (en) RAF inhibitor compounds and methods
WO2007127175A3 (en) Pharmaceutical compounds
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
WO2007027855A3 (en) Raf inhibitor compounds and methods of use thereof
SG178900A1 (en) Raf inhibitor compounds and methods of use thereof